Protocol Ledger

NCT03795428 · Phase II · TERMINATED

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

Interventional Phase II clinical trial protocol NCT03795428 sponsored by PhaseBio Pharmaceuticals in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-10 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03795428
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03795428
Protocol FieldVerified Registry Value
NCT IdentifierNCT03795428
Consolidated Lead SponsorPhaseBio Pharmaceuticals
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2019-04-10
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI